Figure 1.
Study design. A total of 230 patients with DLBCL were treated at the IEO, Milan, Italy, from 2010 to 2018. Only patients with available FFPE tissue and baseline FDG-PET scan performed at IEO were initially considered in this analysis. Fifty-six patients had a FDG-PET scan performed before the initial diagnostic biopsy, with available FFPE tissue for molecular analyses. T-GEP success rate was 85.7% (n = 48), with 8 cases not yielding enough high-quality mRNA to undergo successful GEP assessment. Only cases of not otherwise specified (NOS) histology (including those originally diagnosed as DLBCL-NOS and now included in the high-grade B-cell lymphoma provisional category) were considered. Forty-eight patients with NOS-DLBCL with available baseline FDG-PET and mRNA extracted from FFPE tissue samples were finally included in the discovery cohort. A GEP–based metabolic signature (MetSig) was generated in the discovery cohort and validated in silico in 2 large, publicly available DLBCL cohorts (Sha et al and Lenz et al).34,35 A RadSig was generated in the discovery cohort and validated in an independent series of 64 patients with available baseline FDG-PET scan performed at IEO in the same time frame. FFPE tissue for T-GEP was not available in the validation cohort. IEO, European Institute of Oncology; SUV max, standardized uptake value maximum.

Study design. A total of 230 patients with DLBCL were treated at the IEO, Milan, Italy, from 2010 to 2018. Only patients with available FFPE tissue and baseline FDG-PET scan performed at IEO were initially considered in this analysis. Fifty-six patients had a FDG-PET scan performed before the initial diagnostic biopsy, with available FFPE tissue for molecular analyses. T-GEP success rate was 85.7% (n = 48), with 8 cases not yielding enough high-quality mRNA to undergo successful GEP assessment. Only cases of not otherwise specified (NOS) histology (including those originally diagnosed as DLBCL-NOS and now included in the high-grade B-cell lymphoma provisional category) were considered. Forty-eight patients with NOS-DLBCL with available baseline FDG-PET and mRNA extracted from FFPE tissue samples were finally included in the discovery cohort. A GEP–based metabolic signature (MetSig) was generated in the discovery cohort and validated in silico in 2 large, publicly available DLBCL cohorts (Sha et al and Lenz et al).34,35 A RadSig was generated in the discovery cohort and validated in an independent series of 64 patients with available baseline FDG-PET scan performed at IEO in the same time frame. FFPE tissue for T-GEP was not available in the validation cohort. IEO, European Institute of Oncology; SUV max, standardized uptake value maximum.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal